Report Description

The global stomach cancer treatment market is anticipated to witness an impressive growth during the forecast period. This can be ascribed to the growing development of novel drugs and therapies for treating stomach cancer. Additionally, growing demand for painless low-cost treatment and favorable reimbursement scenario for the treatment of cancer have significantly increased the growth of stomach cancer treatment across different parts of the globe. Additionally, growing aging population across the globe which is more prone to different kinds of chronic diseases like stomach cancer is further expected to increase the demand for different cancer therapies, thereby fuelling the market growth through 2028. Besides, growing awareness about the benefits of new therapies, with increasing expenditure on cancer diseases worldwide is further expected to support the stomach cancer treatment market during the forecast period. Surgery is often the first line of treatment for stomach cancer, particularly for early-stage disease. During surgery, the tumor and surrounding tissue are removed, which can help to prevent the cancer from spreading to other parts of the body. In some cases, the entire stomach may need to be removed, a procedure known as a gastrectomy. While surgery can be highly effective for early-stage stomach cancer, it may be less effective for more advanced disease. The cost of stomach cancer treatment can be very high, particularly for advanced treatments such as targeted therapy and immunotherapy. This can be a barrier to accessing treatment for many patients, particularly in developing countries. Stomach cancer treatment can be associated with a number of side effects, which can impact patients' quality of life. This can make it difficult for patients to continue with their treatment regimen and can reduce the effectiveness of treatment. Despite the high prevalence of stomach cancer, there is still a lack of awareness about the disease and its treatment options. This can lead to delays in diagnosis and treatment, which can impact patients' outcomes. Like many other types of cancer, stomach cancer can develop resistance to certain treatments over time. This can make it difficult to achieve long-term remission and can limit the effectiveness of treatment options. While advanced treatments such as targeted therapy and immunotherapy are available for stomach cancer, they may not be widely available in all regions. This can limit patients' access to the most effective treatments and can impact the growth of the market.

Growing Prevalence of Stomach Cancer

Increasing incidence of adenocarcinoma, lymphoma, and gastrointestinal stromal tumours across the world are driving the market growth during the forecast period. Similarly, rising aging population is susceptible to chronic diseases like stomach cancer, which is one of the most common deadly cancers worldwide, especially among older males. This is expected to boost the market growth in the forecast period. According to National Cancer Institute, in 2022, 26,380 new stomach cancer cases and 11,090 deaths are estimated in the United States. In developing countries, stomach cancer is more diagnosed in males than females because of females carry an extra copy of certain protective genes in their cells that men don't have. Increasing prevalence of gastric cancer in the region is demanding effective therapies for treating patients which, in turn, is expected to propel the market growth during the forecast period. For instance, according to the 2021 statistics published by the Canadian Cancer Society, 4,000 Canadians were affected to gastric cancer. Precision medicine involves tailoring treatments to the specific genetic characteristics of a patient's tumor. This approach is becoming increasingly common in the treatment of stomach cancer, with more and more patients undergoing genetic testing to determine the best treatment options for their individual needs. Stomach cancer is a highly prevalent disease, with millions of people affected by it worldwide. The increasing incidence of stomach cancer is driving the demand for effective treatment options, which is in turn fueling the growth of the global stomach cancer treatment market. As patients and healthcare providers become more aware of the benefits of early detection and treatment of stomach cancer, there is a growing demand for effective treatment options. This is driving the development of new drugs and therapies, as well as the adoption of advanced technologies in cancer treatment. Finally, there is growing recognition of the importance of patient-centered care in the treatment of stomach cancer. This means taking into account not just the physical symptoms of the disease, but also the emotional, social, and financial impacts on patients and their families. As a result, there is increasing emphasis on providing comprehensive support and resources for patients throughout their treatment journey. In recent years, a number of new drugs have been approved for the treatment of stomach cancer, including targeted therapies and immunotherapies. For example, in 2021, the US FDA approved trastuzumab deruxtecan (Enhertu) for the treatment of HER2-positive stomach cancer. This drug has shown promising results in clinical trials, and could provide a new treatment option for patients with this type of cancer.

Growing Development in Healthcare Industry

Increasing approval of newly developed drug from the government along with growing prevalence of stomach cancer is expected to create a lucrative growth prospect for the stomach cancer market over the years. Research & Development activities play a major role in developing novel drugs and therapies. For instance, a research team from Taiwan has recently launched two gastric cancer biomarkers. This advancement may bring remarkable growth prospects for the stomach cancer market, thereby boosting the market growth. Similarly, oral drugs are expected to boost the market growth during forecast period as most products are available in capsule and tablet, making it a very feasible route of administration. Growing health awareness among the population is expected to boost the stomach cancer treatment market growth. The innovative therapy launches for treating gastric cancer are expected to enhance the market simultaneously. Different researchers and government organizations are investing for the development novel drugs that benefit the market as well as patient, this creates more opportunities in the market. It is estimated that 11,090 deaths (6,690 men and 4,400 women) from this disease will occur in the United States in 2022. In 2020, an estimated 768,793 people died from stomach cancer worldwide. Surgery remains an important treatment option for stomach cancer, and recent advances in surgical techniques have made it possible to remove tumors more safely and effectively. For example, minimally invasive surgery (such as laparoscopic and robotic surgery) can reduce the risk of complications and speed up recovery times for patients. The increasing investments in healthcare infrastructure, particularly in developing countries, is driving the growth of the global stomach cancer treatment market. This is improving access to healthcare services and increasing the demand for effective treatments for stomach cancer. The global stomach cancer treatment market is being driven by an increasing focus on research and development activities. Healthcare providers and researchers are working to develop new and innovative treatments for stomach cancer, which is driving the growth of the market.

Recent Development

  • For instance, in April 2021, the U.S. FDA approved Bristol-Myers Squibb Company’s product Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of metastatic gastric cancer.
  • Enhertu is a targeted therapy that was approved by the US FDA in 2019 for the treatment of HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. The drug is a combination of an antibody and a chemotherapy agent, and targets the HER2 protein that is overexpressed in some types of stomach cancer. In clinical trials, Enhertu has shown promising results in improving overall survival and reducing the risk of disease progression.
  • Tukysa is another targeted therapy that was approved by the US FDA in 2020 for the treatment of HER2-positive advanced or metastatic gastric or GEJ adenocarcinoma. Like Enhertu, Tukysa targets the HER2 protein, but works by blocking the activity of enzymes that promote cancer growth. In clinical trials, Tukysa has been shown to improve progression-free survival and overall survival compared to standard chemotherapy.


Download Free Sample Report

Market Segmentation

The global stomach cancer treatment market can be segmented by treatment type, by cancer type, by route of administration, by drug class, by distribution channel and by region. Based on treatment type, the market can be segmented into Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, Others. Based on cancer type, the market can be differentiated into Gastric Cancer/Gastroesophageal Junction Cancer v/s Gastrointestinal Stromal Tumors. Based on route of administration, the market can be divided into Oral v/s Injectables. Based on drug class, the market can be segmented into PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Others. Based on distribution channel, the market can be grouped into Hospital Pharmacies, Specialty Pharmacies, Others. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, United States dominated the global stomach cancer treatment market on account of growing demand for advance cancer therapy in the country.

Market Players

Pfizer, Inc., Novartis International AG, Eli Lilly and Company, Bristol Myers Squibb Company, Teva Pharmaceutical Industries AG, F. Hoffmann La Roche AG, Mylan N.V., Celltrion Healthcare Co., Ltd, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd. are some of the leading players operating in the Global Stomach Cancer Treatment Market.

Download Sample Report

Report Scope:

In this report, global stomach cancer treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  •    Stomach Cancer Treatment Market, By Treatment Type:

o    Immunotherapy

o    Targeted Therapy

o    Chemotherapy

o    Radiation Therapy

o    Others

  •    Stomach Cancer Treatment Market, By Cancer Type:

o    Gastric Cancer/Gastroesophageal Junction Cancer

o    Gastrointestinal Stromal Tumors

  • Stomach Cancer Treatment Market, By Route of Administration:

o    Oral

o    Injectables

  • Stomach Cancer Treatment Market, By Drug Class:

o    PD-1/PD-L1 Inhibitors

o    HER2 Antagonists

o    VEGFR2 Antagonists

o    Others

  • Stomach Cancer Treatment Market, By Distribution Channel:

o    Hospital Pharmacies

o    Specialty Pharmacies

o    Others

  • Stomach Cancer Treatment Market, By Region:
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • United Kingdom
      • Italy
      • Spain
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Australia
    • South America
      • Brazil
      • Argentina
      • Colombia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE
      • Turkey
      • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Stomach Cancer Treatment Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Stomach Cancer Treatment Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Stomach Cancer Treatment Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value

5.2.  Market Share & Forecast

5.2.1.     By Treatment Type (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, Others)

5.2.2.     By Cancer Type (Gastric Cancer/Gastroesophageal Junction Cancer v/s Gastrointestinal Stromal Tumors)

5.2.3.     By Route of Administration (Oral v/s Injectables)

5.2.4.     By Drug Class (PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Others)

5.2.5.     By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Others)

5.2.6.     By Region

5.2.7.     By Company (2022)

5.3.  Market Map

5.3.1.     By Treatment Type

5.3.2.     By Cancer Type

5.3.3.     By Route of Administration

5.3.4.     By Drug Class

5.3.5.     By Distribution Channel

5.3.6.     By Region

6.    North America Stomach Cancer Treatment Market Outlook

6.1.  Market Size & Forecast          

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Treatment Type

6.2.2.     By Cancer Type

6.2.3.     By Route of Administration

6.2.4.     By Drug Class

6.2.5.     By Distribution Channel

6.2.6.     By Country

6.3.  North America: Country Analysis

6.3.1.     United States Stomach Cancer Treatment Market Outlook

6.3.1.1.         Market Size & Forecast

6.3.1.1.1.             By Value

6.3.1.2.         Market Share & Forecast

6.3.1.2.1.             By Treatment Type

6.3.1.2.2.             By Cancer Type

6.3.1.2.3.             By Route of Administration

6.3.1.2.4.             By Drug Class

6.3.1.2.5.             By Distribution Channel

6.3.2.     Canada Stomach Cancer Treatment Market Outlook

6.3.2.1.         Market Size & Forecast

6.3.2.1.1.             By Value

6.3.2.2.         Market Share & Forecast

6.3.2.2.1.             By Treatment Type

6.3.2.2.2.             By Cancer Type

6.3.2.2.3.             By Route of Administration

6.3.2.2.4.             By Drug Class

6.3.2.2.5.             By Distribution Channel

6.3.3.     Mexico Stomach Cancer Treatment Market Outlook

6.3.3.1.         Market Size & Forecast

6.3.3.1.1.             By Value

6.3.3.2.         Market Share & Forecast

6.3.3.2.1.             By Treatment Type

6.3.3.2.2.             By Cancer Type

6.3.3.2.3.             By Route of Administration

6.3.3.2.4.             By Drug Class

6.3.3.2.5.             By Distribution Channel

7.    Europe Stomach Cancer Treatment Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Treatment Type

7.2.2.     By Cancer Type

7.2.3.     By Route of Administration

7.2.4.     By Drug Class

7.2.5.     By Distribution Channel

7.2.6.     By Country

7.3.  Europe: Country Analysis

7.3.1.     France Stomach Cancer Treatment Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Treatment Type

7.3.1.2.2.             By Cancer Type

7.3.1.2.3.             By Route of Administration

7.3.1.2.4.             By Drug Class

7.3.1.2.5.             By Distribution Channel

7.3.2.     Germany Stomach Cancer Treatment Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Treatment Type

7.3.2.2.2.             By Cancer Type

7.3.2.2.3.             By Route of Administration

7.3.2.2.4.             By Drug Class

7.3.2.2.5.             By Distribution Channel

7.3.3.     United Kingdom Stomach Cancer Treatment Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Treatment Type

7.3.3.2.2.             By Cancer Type

7.3.3.2.3.             By Route of Administration

7.3.3.2.4.             By Drug Class

7.3.3.2.5.             By Distribution Channel

7.3.4.     Italy Stomach Cancer Treatment Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Treatment Type

7.3.4.2.2.             By Cancer Type

7.3.4.2.3.             By Route of Administration

7.3.4.2.4.             By Drug Class

7.3.4.2.5.             By Distribution Channel

7.3.5.     Spain Stomach Cancer Treatment Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Treatment Type

7.3.5.2.2.             By Cancer Type

7.3.5.2.3.             By Route of Administration

7.3.5.2.4.             By Drug Class

7.3.5.2.5.             By Distribution Channel

8.    Asia-Pacific Stomach Cancer Treatment Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Treatment Type

8.2.2.     By Cancer Type

8.2.3.     By Route of Administration

8.2.4.     By Drug Class

8.2.5.     By Distribution Channel

8.2.6.     By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.     China Stomach Cancer Treatment Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Treatment Type

8.3.1.2.2.             By Cancer Type

8.3.1.2.3.             By Route of Administration

8.3.1.2.4.             By Drug Class

8.3.1.2.5.             By Distribution Channel

8.3.2.     India Stomach Cancer Treatment Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Treatment Type

8.3.2.2.2.             By Cancer Type

8.3.2.2.3.             By Route of Administration

8.3.2.2.4.             By Drug Class

8.3.2.2.5.             By Distribution Channel

8.3.3.     Japan Stomach Cancer Treatment Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Treatment Type

8.3.3.2.2.             By Cancer Type

8.3.3.2.3.             By Route of Administration

8.3.3.2.4.             By Drug Class

8.3.3.2.5.             By Distribution Channel

8.3.4.     South Korea Stomach Cancer Treatment Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Treatment Type

8.3.4.2.2.             By Cancer Type

8.3.4.2.3.             By Route of Administration

8.3.4.2.4.             By Drug Class

8.3.4.2.5.             By Distribution Channel

8.3.5.     Australia Stomach Cancer Treatment Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Treatment Type

8.3.5.2.2.             By Cancer Type

8.3.5.2.3.             By Route of Administration

8.3.5.2.4.             By Drug Class

8.3.5.2.5.             By Distribution Channel

9.    South America Stomach Cancer Treatment Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Treatment Type

9.2.2.     By Cancer Type

9.2.3.     By Route of Administration

9.2.4.     By Drug Class

9.2.5.     By Distribution Channel

9.2.6.     By Country

9.3.  South America: Country Analysis

9.3.1.     Brazil Stomach Cancer Treatment Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Treatment Type

9.3.1.2.2.             By Cancer Type

9.3.1.2.3.             By Route of Administration

9.3.1.2.4.             By Drug Class

9.3.1.2.5.             By Distribution Channel

9.3.2.     Argentina Stomach Cancer Treatment Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Treatment Type

9.3.2.2.2.             By Cancer Type

9.3.2.2.3.             By Route of Administration

9.3.2.2.4.             By Drug Class

9.3.2.2.5.             By Distribution Channel

9.3.3.     Colombia Stomach Cancer Treatment Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Treatment Type

9.3.3.2.2.             By Cancer Type

9.3.3.2.3.             By Route of Administration

9.3.3.2.4.             By Drug Class

9.3.3.2.5.             By Distribution Channel

10.  Middle East and Africa Stomach Cancer Treatment Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Treatment Type

10.2.2.  By Cancer Type

10.2.3.  By Route of Administration

10.2.4.  By Drug Class

10.2.5.  By Distribution Channel

10.2.6.  By Country

10.3.              MEA: Country Analysis

10.3.1.  South Africa Stomach Cancer Treatment Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Treatment Type

10.3.1.2.2.           By Cancer Type

10.3.1.2.3.           By Route of Administration

10.3.1.2.4.           By Drug Class

10.3.1.2.5.           By Distribution Channel

10.3.2.  Saudi Arabia Stomach Cancer Treatment Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Treatment Type

10.3.2.2.2.           By Cancer Type

10.3.2.2.3.           By Route of Administration

10.3.2.2.4.           By Drug Class

10.3.2.2.5.           By Distribution Channel

10.3.3.  UAE Stomach Cancer Treatment Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Treatment Type

10.3.3.2.2.           By Cancer Type

10.3.3.2.3.           By Route of Administration

10.3.3.2.4.           By Drug Class

10.3.3.2.5.           By Distribution Channel

10.3.4.  Turkey Stomach Cancer Treatment Market Outlook

10.3.4.1.      Market Size & Forecast

10.3.4.1.1.           By Value

10.3.4.2.      Market Share & Forecast

10.3.4.2.1.           By Treatment Type

10.3.4.2.2.           By Cancer Type

10.3.4.2.3.           By Route of Administration

10.3.4.2.4.           By Drug Class

10.3.4.2.5.           By Distribution Channel

10.3.5.  Egypt Stomach Cancer Treatment Market Outlook

10.3.5.1.      Market Size & Forecast

10.3.5.1.1.           By Value

10.3.5.2.      Market Share & Forecast

10.3.5.2.1.           By Treatment Type

10.3.5.2.2.           By Cancer Type

10.3.5.2.3.           By Route of Administration

10.3.5.2.4.           By Drug Class

10.3.5.2.5.           By Distribution Channel

11.  Market Dynamics

11.1.              Drivers

11.2.              Challenges

12.  Market Trends & Developments

12.1.              Recent Developments

12.2.              Mergers & Acquisitions

12.3.              Product Launches

13.  Competitive Landscape

13.1.              Business Overview

13.2.              Product Offerings

13.3.              Recent Developments

13.4.              Financials (As Reported)

13.5.              Key Personnel

13.6.              SWOT Analysis

13.6.1.  Pfizer, Inc.

13.6.2.  Novartis International AG

13.6.3.  Eli Lilly and Company

13.6.4.  Bristol Myers Squibb Company

13.6.5.  Teva Pharmaceutical Industries AG

13.6.6.  F. Hoffmann La Roche AG

13.6.7.  Mylan N.V.

13.6.8.  Celltrion Healthcare Co., Ltd

13.6.9.  Merck & Co., Inc.

13.6.10.                Teva Pharmaceutical Industries Ltd.

Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

Increasing geriatric population across the globe combined with changes in sedentary lifestyle due to alcohol consumption, smoking, etc. are some of the major factors driving the growth of global stomach cancer treatment market.

down-arrow

Pfizer, Inc., Novartis International AG, Eli Lilly and Company, Bristol Myers Squibb Company, Teva Pharmaceutical Industries AG, F. Hoffmann La Roche AG, Mylan N.V., Celltrion Healthcare Co., Ltd, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd. are some of the leading players operating in the Global Stomach Cancer Treatment Market.

down-arrow

The Immunotherapy is expected to dominate the global stomach cancer treatment market during the forecast period.

down-arrow

North America region is expected to hold the largest share in the Global Stomach Cancer Treatment Market.

profile

Sakshi Bajaal

Business Consultant
Press Release

Stomach Cancer Treatment Market to be dominated by Immunotherapy type through 2028

Dec, 2022

Growing prevalence of stomach cancer is expected to drive the growth of global stomach cancer treatment in the forecast period, 2024-2028.